Search results - 5 results
Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.
cervical cancer screening should be clinically validated according to international criteria. OncoPredict HPV ® Screening (SCR) is a partial genotyping multiplex real-time PCR assay targeting E6 / E7 genes ...
Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
reproducibility and non-inferior clinical accuracy for cervical precancer compared to a standard comparator assay. The international reproducibility criteria are: lower bound of 95% confidence interval of the ...
Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
screening need to be identified. A systematic review was conducted to answer the question which hrHPV tests fulfil the criteria defined by an international expert team in 2009, based on reproducibility and ...
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
Oligonucleotide Probes Papillomaviridae Papillomavirus Infections Reference Standards Sensitivity and Specificity Young adult Abstract: The LMNX genotyping kit HPV GP (LMNX) is based on the clinically validated GP5 ...
Description of cervical cancer mortality in Belgium using Bayesian age-period-cohort models.
from the WHO mortality database together with population data for Belgium and the Netherlands. Different ICD (International Classification of Diseases) were used over time for death cause certification. ...